BPC-157

 

1.0 Introduction to Gastric Pentadecapeptide BPC-157

 

1.1 Discovery, Origin, and Physicochemical Properties

Gastric Pentadecapeptide BPC-157, also known as Body Protection Compound 157, PL 14736, or bepecin, is a synthetic peptide composed of a chain of 15 amino acids.1 Its discovery originated from investigations into the endogenous (originating from within an organism) protective mechanisms of the mammalian gastrointestinal tract. Specifically, it was first identified and isolated as a fragment of a larger, naturally occurring protein called Body Protection Compound (BPC), which is present in human gastric juice.3

The context of its origin is fundamental to understanding its primary biological characterization. The gastric mucosa possesses a remarkable capacity to withstand a highly acidic and enzymatically aggressive environment, a phenomenon extensively studied under the concept of “gastric cytoprotection”.6 This term, first introduced by Andre Robert, describes the ability of the stomach lining to resist injury from a wide variety of noxious agents. The BPC protein, and by extension its active fragment BPC-157, is considered a key mediator of this innate protective system. Consequently, the initial wave of research focused logically on its gastroprotective and anti-ulcer properties. The subsequent observation that these protective effects were not confined to the stomach but could be observed in a multitude of other organ systems led to the broader concept of “organoprotection,” suggesting that BPC-157 interacts with fundamental and evolutionarily conserved healing pathways common to many different tissues.6 This investigative path—from a specific observation in gastric juice to a generalized systemic effect—indicates that BPC-157’s therapeutic potential was uncovered through physiological exploration rather than through a targeted drug design process aimed at a single disease receptor.

 

1.2 Structural Composition and Remarkable Stability

The primary structure of BPC-157 consists of the specific 15-amino-acid sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.1 A defining feature of this sequence is a triple proline motif (Pro-Pro-Pro) located near the N-terminus. Proline is a unique amino acid that introduces a rigid kink into peptide chains, and repeating proline motifs are known to confer significant resistance to enzymatic degradation, a process known as proteolysis.8

This structural feature is responsible for one of BPC-157’s most distinctive and clinically relevant characteristics: its exceptional stability. Unlike the vast majority of therapeutic peptides, which are notoriously fragile and rapidly degraded by proteases in the digestive system and bloodstream, BPC-157 demonstrates remarkable resilience.9 It is highly resistant to hydrolysis (chemical breakdown by water) and enzymatic digestion, and it can remain structurally intact in the highly acidic environment of human gastric juice (pH 3.0) for over 24 hours.4 This stability extends to other environmental stressors, as it has also been noted to be resistant to degradation from Ultraviolet (UV) light exposure.10

This inherent stability is a significant departure from the norm in peptide pharmacology. Most peptide-based drugs have poor oral bioavailability and must be administered parenterally (via injection) to bypass the gastrointestinal tract. BPC-157’s ability to survive gastric transit allows for the possibility of oral administration while still achieving systemic effects, a considerable advantage for therapeutic development.12 Furthermore, this persistence is not merely a passive property but a key enabler of its wide-ranging biological activities. A peptide that is rapidly cleared can only interact with fast-acting cell surface receptors. In contrast, BPC-157’s extended presence in biological systems allows it to modulate more complex and slower-acting intracellular processes, such as the regulation of gene expression and the multi-step cascade of angiogenesis. This sustained bioavailability is a fundamental prerequisite for the pleiotropic regenerative effects observed across numerous preclinical studies.

 

2.0 Core Molecular Mechanisms of Action

The therapeutic potential of BPC-157 observed in preclinical models stems from its ability to modulate a complex and interconnected network of molecular signaling pathways. It does not appear to function through a single, high-affinity receptor but rather as a pleiotropic regulator that orchestrates multiple facets of the cellular response to injury. Its mechanisms converge on key processes in tissue repair: angiogenesis, cell migration, growth factor signaling, and the resolution of inflammation.

Table 1: Summary of Key Molecular Pathways Modulated by BPC-157
Pathway/Target Primary Biological Outcome Key Cellular Players/Tissues
VEGFR2-Akt-eNOS Axis Angiogenesis, Endothelial Cell Proliferation/Migration Endothelial Cells
Growth Hormone Receptor (GHR) / JAK2-STAT Pathway Sensitization to Growth Hormone, Cell Proliferation Tendon Fibroblasts
FAK-Paxillin Pathway Cellular Adhesion/Migration, Cytoskeletal Reorganization Tendon Fibroblasts
Nitric Oxide (NO) System Vasodilation, Cytoprotection, Antioxidant Effects Endothelial Cells, General Tissues
Cytokine Modulation (TNF-α, IL-6) Anti-inflammatory Response General Inflamed Tissues

 

2.1 Angiogenesis and Vascular Endothelium Modulation

A central tenet of BPC-157’s regenerative capacity is its potent pro-angiogenic effect. Angiogenesis—the formation of new blood vessels from pre-existing ones—is a critical process in wound healing, as it re-establishes the delivery of oxygen, nutrients, and reparative cells to damaged tissue.2 BPC-157 appears to exert fine-tuned control over this process through multiple, synergistic mechanisms.

 

2.1.1 The VEGFR2-Akt-eNOS Signaling Axis

The primary pathway governing angiogenesis is initiated by Vascular Endothelial Growth Factor (VEGF) binding to its cognate receptor, VEGFR2, on the surface of endothelial cells.22 Preclinical studies have consistently demonstrated that BPC-157 is a powerful modulator of this axis.14 However, its mechanism is nuanced. Instead of increasing the concentration of the signaling molecule VEGF-A, BPC-157 significantly upregulates the expression of the receptor, VEGFR2, at both the mRNA and protein levels.15 This action effectively sensitizes endothelial cells, making them hyper-responsive to the ambient levels of VEGF naturally present at an injury site.

This process can be conceptualized as increasing the number of “antennas” on a cell to better receive a weak signal, rather than simply shouting the signal louder. BPC-157 also promotes the internalization of VEGFR2, a crucial step for the activation and propagation of its downstream signal.15 Once activated, VEGFR2 initiates an intracellular signaling cascade involving the phosphorylation (a chemical modification that typically activates a protein) of the kinase Akt and subsequently, endothelial Nitric Oxide Synthase (eNOS). This complete cascade, known as the VEGFR2-Akt-eNOS pathway, is a cornerstone of BPC-157’s pro-angiogenic and cytoprotective effects.14

 

2.1.2 The Role of Nitric Oxide (NO) System Regulation

The activation of eNOS via the aforementioned pathway results in the increased synthesis of Nitric Oxide (NO), a gaseous signaling molecule with profound effects on the vasculature.15 NO is a potent vasodilator, meaning it relaxes the smooth muscle of blood vessels, increasing their diameter and enhancing blood flow to the injured area.12 This vasodilation is critical for delivering the necessary resources for repair. Studies have confirmed that the vasodilatory effect of BPC-157 is indeed mediated by NO.19

Beyond the VEGFR2-dependent pathway, BPC-157 also appears to activate eNOS through a VEGF-independent mechanism involving Src kinase and Caveolin-1 (Cav-1).14 Cav-1 is a protein that normally binds to and inhibits eNOS. BPC-157 promotes the phosphorylation of Cav-1, causing it to release eNOS and thereby relieving this inhibition, leading to further NO production.19

Critically, BPC-157’s interaction with the NO system appears to be homeostatic rather than purely stimulatory. It exhibits a remarkable ability to normalize NO signaling. In animal models, it has been shown to protect against the tissue damage caused by both NO-synthase inhibitors (e.g., L-NAME), which create a state of NO deficiency, and by NO precursors (e.g., L-arginine), which can create a state of NO excess.18 This dual action is inconsistent with a simple NO agonist. Instead, it suggests BPC-157 functions as a sophisticated modulator or buffer of the NO system, promoting its beneficial, localized effects on healing while preventing the systemic dysregulation that can lead to pathology. This is further supported by its potent antioxidant properties, as it has been shown to reduce the formation of damaging free radicals that can be a byproduct of dysregulated NO pathways.10

 

2.1.3 ERK1/2 Pathway Activation and Endothelial Repair

In conjunction with its effects on vascular tone and growth, BPC-157 directly influences the behavior of the endothelial cells that form the blood vessel walls. It achieves this through the activation of the Extracellular signal-Regulated Kinase (ERK1/2) pathway.14 Phosphorylation of ERK1/2 is a pivotal signaling event that drives fundamental cellular processes required for tissue repair, including cell proliferation, migration, and survival.17 Pharmacological blockade of the ERK pathway has been shown to abolish the pro-migratory effects of BPC-157 on endothelial cells, confirming the pathway’s critical role.17 The activation of ERK1/2 leads to the downstream expression of several transcription factors, including c-Fos, c-Jun, and Early Growth Response-1 (Egr-1), which in turn regulate a suite of genes involved in cell cycle progression and angiogenesis.14 This mechanism provides a direct link between BPC-157 exposure and the mobilization of the cellular “construction crews” needed to repair damaged vasculature and build new tissue.

 

2.2 Growth Factor Receptor Sensitization and Downstream Signaling

Another major axis of BPC-157’s mechanism of action involves its ability to modulate cellular sensitivity to endogenous growth factors, most notably Growth Hormone (GH). This suggests that BPC-157 may not only act directly but also function as a powerful adjuvant, amplifying the body’s own primary anabolic and regenerative signals.

 

2.2.1 Upregulation of the Growth Hormone Receptor (GHR)

In studies utilizing cultured tendon fibroblasts—cells critical for tendon repair but known for their slow metabolic activity—BPC-157 was identified as a potent upregulator of Growth Hormone Receptor (GHR) expression.4 It was shown to increase both the mRNA and protein levels of GHR in a manner that was dependent on both the dose and duration of exposure.4 The functional consequence of this upregulation was significant: fibroblasts pre-treated with BPC-157 exhibited a potentiated proliferative response when subsequently exposed to GH.4

This mechanism represents a significant conceptual advance in understanding how BPC-157 achieves its remarkable effects in slow-healing, poorly vascularized tissues like tendons. Growth Hormone is a primary driver of tissue repair, but its efficacy is entirely dependent on the presence of its receptor on target cells.31 By dramatically increasing the density of GHRs on fibroblasts, BPC-157 effectively “primes” these cells, making them hyper-responsive to the body’s natural regenerative signals. It transforms them into more active participants in the healing process. This suggests that BPC-157’s power may lie not in being a growth factor itself, but in its ability to amplify the effects of the most potent one already present in the body.

 

2.2.2 Activation of the Janus Kinase 2 (JAK2)-STAT Pathway

The functional significance of GHR upregulation is confirmed by the activation of its downstream signaling machinery. The canonical signaling pathway for the GHR involves the Janus Kinase 2 (JAK2) and Signal Transducer and Activator of Transcription (STAT) proteins.31 Research has verified that when BPC-157-pretreated tendon fibroblasts are stimulated with GH, there is a time-dependent increase in the phosphorylation (activation) of JAK2.4 This activation of the JAK2-STAT pathway leads to a tangible biological outcome: increased cell proliferation, as measured by the elevated expression of Proliferating Cell Nuclear Antigen (PCNA), a key marker of cell division.16 This confirms that BPC-157 not only increases the number of GHRs but also ensures they are fully coupled to the intracellular signaling cascades that translate the GH signal into a pro-regenerative cellular response.

 

2.3 Cellular Adhesion, Migration, and Cytoskeletal Dynamics

For tissue repair to occur, reparative cells must physically move into the wound bed, adhere to the extracellular matrix, and begin rebuilding. BPC-157 directly influences this mechanical process by modulating the machinery of cell motility.

 

2.3.1 The Focal Adhesion Kinase (FAK)-Paxillin Pathway

The migration and spreading of tendon fibroblasts are significantly promoted by BPC-157, an effect mediated by the activation of the Focal Adhesion Kinase (FAK)-paxillin pathway.5 FAK and paxillin are scaffolding proteins that are central components of focal adhesions—the complex structures that physically connect a cell’s internal cytoskeleton to the external matrix.33 These connections are not static; they are dynamic hubs that regulate cell adhesion, movement, and survival. Studies have shown that BPC-157 dose-dependently increases the phosphorylation of both FAK and paxillin, which is the key step in their activation, without affecting the total amount of these proteins in the cell.5 The activation of this pathway provides a direct molecular explanation for the accelerated outgrowth of tendon explants and enhanced wound closure observed in in vitro models, as it effectively engages the “engine” of cellular motility.

 

2.3.2 Induction of F-Actin Formation in Fibroblasts

The biochemical activation of the FAK-paxillin pathway is accompanied by a tangible change in cell structure. BPC-157 treatment has been shown to induce the formation of filamentous actin (F-actin) in fibroblasts.5 F-actin polymers assemble into microfilaments that form the primary structural component of the cell’s cytoskeleton. This reorganization of the internal scaffolding is essential for a cell to change shape, extend protrusions, and generate the contractile forces necessary to migrate through tissue. The observation of increased F-actin formation provides a physical, morphological corroboration of the signaling data, linking the activation of the FAK-paxillin pathway to the structural changes required for cell movement.

 

2.4 Cytoprotective and Anti-Inflammatory Pathways

While promoting pro-regenerative processes, BPC-157 simultaneously acts to create a more favorable environment for healing by mitigating inflammation and protecting cells from stress-induced damage.

 

2.4.1 Modulation of Pro-inflammatory Cytokines

Chronic or excessive inflammation is a major impediment to effective tissue repair. BPC-157 has demonstrated significant anti-inflammatory properties in a variety of preclinical models. In animal models of inflammatory conditions such as Inflammatory Bowel Disease (IBD) and arthritis, BPC-157 administration led to a marked reduction in the levels of key pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6).6 Further studies have shown it can also inhibit the expression of other inflammatory mediators like inducible nitric oxide synthase (iNOS) and interferon-gamma (IFNγ).35 By dampening this inflammatory cascade, BPC-157 not only alleviates symptoms like pain and swelling but, more importantly, it shifts the local tissue environment from a state of persistent, self-perpetuating damage to one that is permissive for active repair.

 

2.4.2 Antioxidant Effects and Free Radical Scavenging

A key component of BPC-157’s cytoprotective action is its ability to counteract oxidative stress. Injury and inflammation lead to the production of reactive oxygen species (free radicals), which can cause widespread damage to cellular components and trigger apoptosis (programmed cell death). BPC-157 has been shown to possess powerful antioxidant properties, reducing the formation of free radicals and significantly increasing cell survival under conditions of oxidative stress, such as exposure to hydrogen peroxide ().5 This protective effect is mediated, in part, by its ability to upregulate the expression of endogenous antioxidant enzymes and cytoprotective factors, such as heme oxygenase-1 (HO-1).14 By neutralizing these damaging molecules, BPC-157 helps to preserve the viability of the cellular population required for successful tissue regeneration.

 

3.0 Preclinical Evidence and Potential Therapeutic Applications

The pleiotropic molecular mechanisms of BPC-157 translate into a remarkably broad spectrum of therapeutic effects in preclinical animal models. Research spanning several decades has documented its efficacy in promoting the healing of diverse tissues, from dense connective tissues like tendons and ligaments to complex organs like the brain and gastrointestinal tract. The consistency of these findings across different injury models and organ systems is a hallmark of the BPC-157 literature.

 

Table 2: Overview of Preclinical Research Findings for BPC-157
Tissue/System Injury Model Key Observed Outcomes
Tendon Rat Achilles tendon transection Accelerated functional/biomechanical recovery, increased collagen deposition, fibroblast outgrowth
Ligament Rat medial collateral ligament transection Reduced instability and post-injury contracture, restored biomechanics
Muscle Rat muscle crush, transection, detachment Improved load-to-failure, restored motor function, increased myofibril diameter
Bone Rat segmental bone defect Accelerated callus mineralization, formation of lamellar bone over scar tissue
Stomach Rat – alcohol-induced gastric ulcer, NSAID Rapid ulcer healing, cytoprotection against noxious agents
Intestine Rat cysteamine-induced colitis, anastomotic injury Ameliorated inflammation, fistula closure, improved anastomotic healing
Esophagus Rat reflux esophagitis Reduced esophagitis, normalized sphincter pressure
Pancreas Rat bile duct ligation-induced pancreatitis Reduced inflammation and necrosis, decreased serum amylase
Liver Rat toxin-induced liver damage, ischemia Reduced necrosis and steatosis, protection against NSAID/paracetamol toxicity
Brain Rat traumatic brain injury (TBI), encephalopathy Reduced edema and bleeding, neuronal protection against toxins
Spinal Cord Rat spinal cord compression injury Sustained functional motor recovery, reduced spasticity, counteracted neuronal loss
Peripheral Nerve Rat sciatic nerve transection Accelerated axonal regeneration, improved myelination, restored motor action potentials

 

3.1 Musculoskeletal System Regeneration

Perhaps the most extensively investigated application of BPC-157 is in the realm of musculoskeletal healing, where its pro-angiogenic and growth factor-sensitizing properties are particularly relevant.

 

3.1.1 Tendon and Ligament Healing

Tendons and ligaments are notoriously slow to heal due to their dense, hypovascular nature (meaning they have a poor blood supply).14 BPC-157 has shown remarkable efficacy in overcoming this limitation in animal models. In numerous studies involving the complete transection of the rat Achilles tendon, systemic (injection) or oral administration of BPC-157 led to a dramatic acceleration of the healing process. Treated animals exhibited superior outcomes across a range of metrics, including improved functional recovery, enhanced biomechanical strength (e.g., load to failure), and more organized collagen fiber architecture at the histological level.2 Ex vivo experiments further demonstrated that BPC-157 directly stimulates the outgrowth of tendon fibroblasts from tendon explants, providing a cellular basis for these observations.2 Similar positive results have been reported in models of ligament injury, such as transection of the medial collateral ligament (MCL) in rats, where BPC-157 treatment reduced joint instability and prevented the development of debilitating post-injury contractures.29

 

3.1.2 Muscle Injury Repair and Myogenesis

BPC-157’s regenerative effects extend to skeletal muscle. In preclinical models of direct muscle trauma, including crush injuries, complete transections, and surgical detachment, BPC-157 therapy consistently promoted superior healing outcomes.29 Treated animals showed significantly improved functional recovery, greater macroscopic and myofibril diameters, and increased biomechanical strength of the repaired muscle tissue.39 Mechanistically, BPC-157 has been shown to promote myogenesis (the formation of new muscle fibers) and to accelerate the functional and structural re-establishment of the myotendinous junction—the critical, and often weak, connection point between muscle and tendon.15

 

3.1.3 Bone Fracture Consolidation

The pro-angiogenic properties of BPC-157 are also beneficial for bone healing, as a robust vascular supply is essential for the delivery of osteogenic (bone-forming) cells and minerals to a fracture site. In rat models of segmental bone defects, BPC-157 was shown to significantly accelerate healing.17 One study directly compared its efficacy to standard orthopedic treatments, finding that BPC-157 performed similarly to autologous bone marrow injection and bone grafting. It promoted more rapid and robust callus mineralization and guided the healing process toward the formation of organized, functional lamellar bone rather than non-functional fibrous scar tissue.39

 

3.2 Gastrointestinal Tract Protection and Repair

True to its origin as a gastric peptide, BPC-157 exhibits profound protective and reparative effects throughout the entire gastrointestinal (GI) tract.

 

3.2.1 Healing of Ulcers and Inflammatory Bowel Disease (IBD)

BPC-157 has demonstrated robust efficacy in healing both acute and chronic gastric and duodenal ulcers in rats, including those induced by potent damaging agents like nonsteroidal anti-inflammatory drugs (NSAIDs) and alcohol.6 Its therapeutic action extends to the lower GI tract. In various animal models of Inflammatory Bowel Disease (IBD), such as cysteamine-induced colitis, BPC-157 administration (both oral and parenteral) has been shown to ameliorate inflammation, heal mucosal ulcerations, and counteract the systemic effects of the disease.41 These promising preclinical results prompted early-phase clinical trials in humans for IBD, although the detailed results of these trials have not been widely published in peer-reviewed literature.9

 

3.2.2 Fistula Closure and Anastomotic Healing

One of the most striking demonstrations of BPC-157’s healing capacity is its ability to resolve fistulas—abnormal tunnels that form between organs or between an organ and the skin. In rat models, BPC-157 has successfully healed a variety of surgically induced fistulas, including gastrocutaneous, duodenocutaneous, colocutaneous, and vesicovaginal fistulas.7 This effect appears to be driven by its powerful and rapid pro-angiogenic action, which quickly “recruits” new blood vessels to the site of the defect, providing the necessary substrate for tissue closure.7 Similarly, it has been shown to significantly improve the healing of intestinal anastomoses (surgical reconnections of the bowel), reducing leakage, strengthening the surgical site, and preventing the formation of excessive adhesions.7

 

3.3 Neuroprotective and Neuroregenerative Effects

The therapeutic potential of BPC-157 extends to the central and peripheral nervous systems, where it has demonstrated both protective and regenerative properties.

 

3.3.1 Traumatic Brain (TBI) and Spinal Cord Injury (SCI) Models

In rat models of traumatic brain injury, BPC-157 administration was shown to reduce cerebral edema (swelling) and hemorrhage, key secondary injury mechanisms that exacerbate initial trauma.12 Its effects in spinal cord injury (SCI) models are particularly noteworthy. In a rat model of sacrocaudal spinal cord compression, a single intraperitoneal injection of BPC-157 administered shortly after the injury led to rapid, significant, and sustained functional recovery that persisted for up to a year.13 Treated animals exhibited improved motor function, resolved spasticity, and showed marked preservation of neural tissue at the microscopic level, with BPC-157 counteracting neuronal loss, demyelination, and edema formation.45 BPC-157 has also shown protective effects against more diffuse brain damage (encephalopathies) induced by NSAID overdose or other toxins.12

 

3.3.2 Peripheral Nerve Regeneration

BPC-157 also promotes the healing of peripheral nerves. In a rat model involving the transection of the sciatic nerve, treatment with BPC-157 markedly improved and accelerated the regenerative process. Histological analysis revealed faster and more organized axonal regeneration, increased thickness of the myelin sheath, and improved vascularization of the nerve.47 These structural improvements were correlated with functional gains, including the restoration of motor action potentials and better scores on functional recovery tests.47 Beyond direct neural repair, BPC-157 appears to exert a normalizing influence on central neurotransmitter systems, showing modulatory effects on dopamine, serotonin, and GABA signaling pathways that may contribute to restoring overall nervous system homeostasis after injury.11

 

3.4 Systemic Organoprotection

The concept of “organoprotection” posits that the fundamental cytoprotective mechanisms first observed in the stomach can be generalized to protect cells and maintain endothelial integrity in other organs throughout the body.6 The broad range of BPC-157’s effects in preclinical models provides strong support for this hypothesis.

 

3.4.1 Hepatoprotective and Pancreatoprotective Actions

BPC-157 has demonstrated significant protective effects on the liver and pancreas in various models of toxic and ischemic injury.43 It has been shown to ameliorate the course of acute pancreatitis induced by bile duct ligation, reducing inflammation, necrosis, and serum amylase levels.42 In the liver, it protects against damage from a variety of hepatotoxins, including alcohol, paracetamol, and NSAIDs, and reduces congestion and cellular damage in models of ischemia-reperfusion injury and abdominal compartment syndrome.37 This broad protective capacity underscores the idea that BPC-157 acts on universal mechanisms of cell survival and vascular health, conferring resilience against a wide array of pathological insults across multiple organ systems.

 

4.0 Pharmacokinetics, Human Trials, and Safety Profile

Despite the vast and compelling body of preclinical evidence, the translation of BPC-157 into a clinically validated therapeutic is hindered by a critical lack of human data. Understanding its pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes a drug) and critically evaluating the available human and safety data are essential for contextualizing its potential.

 

4.1 Bioavailability, Metabolism, and Elimination

Pharmacokinetic studies conducted in rats and beagle dogs have provided initial insights into how BPC-157 behaves in the body. Following intravenous (IV) or intramuscular (IM) administration, the peptide is characterized by a very rapid elimination, with a plasma half-life of less than 30 minutes in both species.43 The absolute bioavailability—the fraction of the administered dose that reaches systemic circulation—after an IM injection was found to be approximately 14-19% in rats and significantly higher, at 45-51%, in beagle dogs.43

Studies using radiolabeled BPC-157 indicate that it is metabolized, likely in the liver, into smaller peptide fragments and constituent amino acids. These metabolites then enter normal amino acid metabolic pathways and are primarily excreted via urine and bile.29

The extremely short plasma half-life presents a pharmacological paradox. How can a compound that is cleared from the bloodstream in under 30 minutes produce such profound and sustained biological effects that are observed over days and weeks in healing studies? This discrepancy strongly suggests that BPC-157 does not need to be continuously present to exert its effects. Instead, it likely acts as a potent biological “trigger” or initiator. A brief exposure to the peptide appears sufficient to activate a cascade of downstream cellular processes, such as the upregulation of gene expression for key receptors (VEGFR2, GHR) and signaling molecules (Egr-1). Once initiated, these regenerative programs become self-sustaining, continuing long after the peptide itself has been metabolized and cleared.15 This “initiate and retreat” mechanism is a critical concept for understanding its pharmacology and potential dosing regimens.

 

4.2 Critical Review of Human Clinical Data

The most significant challenge in evaluating BPC-157 is the profound chasm between the extensive preclinical database and the near-total absence of robust human clinical trial data. The evidence for its efficacy and safety in humans is extremely limited, of low methodological quality, and largely unpublished in peer-reviewed journals.55

The few human studies mentioned in the literature include:

  • A Retrospective Knee Pain Study: One frequently cited piece of human evidence is a small, retrospective study involving 12 patients with unspecified chronic knee pain. These patients received intra-articular injections of BPC-157. Of the 12, seven reported subjective pain relief that lasted for more than six months.29 However, this study suffers from severe limitations: it was retrospective (looking back at data, not a planned experiment), had no control or placebo group, involved a very small number of participants, and the diagnosis was not specified. As such, its findings are considered anecdotal and cannot be used to establish efficacy.
  • Unpublished Pilot Studies: There are mentions of other small pilot studies investigating BPC-157 for interstitial cystitis and for intravenous safety and pharmacokinetics.14 While these studies reportedly found no adverse effects, the full data and conclusions have not been published, rendering them unverifiable.
  • Registered Clinical Trials: A Phase I clinical trial was registered on ClinicalTrials.gov (NCT02637284) to assess the safety and pharmacokinetics of an oral tablet formulation of BPC-157 in healthy volunteers.58 However, the status of this trial is unclear, and no results have been posted or published. Similarly, Phase II trials for Inflammatory Bowel Disease (IBD) have been alluded to in the literature, but again, a comprehensive, peer-reviewed publication of the results is not available.9

This lack of high-quality clinical evidence is the central problem surrounding BPC-157. The reasons for this gap are speculative—they could range from a lack of commercial funding, proprietary development by a pharmaceutical company that has not disclosed its data, or the possibility of unpublished negative or inconclusive results. Regardless of the reason, the consequence is that all claims of human efficacy and safety remain unproven and speculative, relying on the extrapolation of animal data and uncontrolled anecdotal reports.56

 

4.3 Preclinical Safety and Toxicology Findings

In stark contrast to the uncertainty in humans, the preclinical safety profile of BPC-157 appears to be exceptionally favorable. Comprehensive toxicology studies have been conducted in multiple species, including mice, rats, rabbits, and dogs.43

Across these studies, BPC-157 was found to be very well tolerated, even at high doses.60 A key finding is that a lethal dose (LD1)—the dose required to be toxic to 1% of the test population—has not been established, indicating that researchers were unable to administer a dose high enough to induce lethal toxicity.6 Furthermore, these studies found no evidence of serious systemic toxicity, genetic toxicity (mutagenicity), or embryo-fetal toxicity (teratogenicity).60 A local tolerance test showed that irritation from injection was mild.61 The only notable adverse effect reported was a transient and reversible decrease in creatinine levels observed in dogs at a high dose (2 mg/kg), which was not seen at lower doses and was suspected to be related to the peptide’s pharmacological activity rather than a toxic effect.61

While this extensive animal safety data is reassuring, it is a fundamental principle of pharmacology that preclinical safety cannot be directly and reliably extrapolated to humans.57 The lack of corresponding clinical safety data in humans remains a major barrier to its legitimate therapeutic use.

 

5.0 Potential Benefits, Safety Concerns, and Future Directions

 

5.1 Synthesizing the Potential Benefits: A Pleiotropic Healing Agent?

Based on the convergence of evidence from decades of preclinical research, BPC-157 can be theorized as a potent, systemic, and pleiotropic healing agent. Its potential benefits are not limited to a single tissue type or injury but appear to span the entire organism. The theoretical therapeutic profile is that of a master orchestrator of the body’s own regenerative systems.

The potential applications are vast, covering musculoskeletal repair (accelerating the healing of tendons, ligaments, muscles, and bones), comprehensive gastrointestinal health (treating ulcers, IBD, and fistulas), neuroprotection and neuroregeneration (mitigating damage from TBI and SCI), and systemic organ protection (shielding the liver, pancreas, and heart from toxic or ischemic insults). Compounding this therapeutic promise are its unique pharmaceutical properties: remarkable stability that allows for oral administration and an exceptionally high safety margin observed in all animal species tested. In theory, these characteristics make BPC-157 one of the most promising and versatile regenerative compounds to have emerged from preclinical research. However, this theoretical potential must be weighed against significant and unresolved concerns.

 

5.2 Major Concerns and Unanswered Questions

The transition from preclinical promise to clinical reality is fraught with challenges, and for BPC-157, these challenges are substantial and multifaceted.

 

5.2.1 The Angiogenesis Paradox: Healing vs. Oncogenic Risk

The most significant scientific concern surrounding BPC-157 stems from one of its primary mechanisms of action: the promotion of angiogenesis.3 While the formation of new blood vessels is absolutely essential for wound healing, it is also a hallmark of cancer. Solid tumors are dependent on angiogenesis to supply them with the oxygen and nutrients required for their growth, invasion, and metastasis (the spread of cancer to distant sites).33

The molecular pathways that BPC-157 potently activates—particularly the VEGFR2 and FAK-paxillin signaling cascades—are the very same pathways that are frequently hijacked by aggressive cancer cells to facilitate their survival and spread.33 This creates a serious and plausible theoretical risk: by systemically upregulating these pathways, BPC-157 might inadvertently promote the growth or metastasis of pre-existing, undiagnosed cancerous or pre-cancerous cells.

There are counterarguments to this concern. Some researchers posit that BPC-157’s effect is modulatory and homeostatic, promoting organized, healthy vascular networks characteristic of healing tissue, rather than the chaotic and leaky vasculature typical of tumors.18 Evidence supporting this view includes a study where BPC-157 inhibited the neovascularization of the cornea—a process that, according to Judah Folkman’s pioneering work on angiogenesis, is an anti-tumor characteristic.28 An older in vitro study also reported that BPC-157 inhibited the growth of a melanoma cell line.33

Despite these nuances, the oncogenic risk remains the most critical and unresolved scientific question. The effect of BPC-157 on cell growth and vascularization may be highly context-dependent. Without long-term human safety data, it is impossible to quantify this risk. Its use in individuals, especially those with a personal or family history of cancer, represents a significant gamble on this crucial unknown.

 

5.2.2 The Chasm Between Preclinical Promise and Clinical Evidence

The second major concern is the overwhelming reliance on animal models.57 The history of drug development is littered with compounds that showed remarkable efficacy in rodents but failed to translate to humans due to differences in metabolism, physiology, or disease pathology. The near-complete absence of published, peer-reviewed, large-scale, randomized controlled trials (RCTs) in humans means that BPC-157’s efficacy for any condition in people remains scientifically unproven.56 The anecdotal reports and small case series that circulate in non-academic circles, often promoted by clinics or individuals with a commercial interest in selling the peptide, are not a valid substitute for rigorous scientific evidence and can be subject to significant bias.57

 

5.3 Regulatory Landscape and Ethical Considerations

The scientific uncertainties surrounding BPC-157 are reflected in its official regulatory status. It is not approved for human clinical use by any major global regulatory agency.

 

Table 3: Regulatory and Safety Status of BPC-157
Organization Status/Classification Rationale/Implication
U.S. Food and Drug Administration (FDA) Not approved for human clinical use. Classified as a Category 2 bulk drug substance, raising significant safety concerns. Lack of human safety and efficacy data. This classification effectively bars its use by compounding pharmacies in medications for patients.17
World Anti-Doping Agency (WADA) Prohibited under the S0 “Unapproved Substances” category. The substance has not undergone sufficient clinical development to ensure its safety and efficacy. It is banned at all times (in- and out-of-competition) for all athletes. No Therapeutic Use Exemption (TUE) is possible.3

The sale and use of BPC-157 for human consumption exist in a legal and ethical gray area. It is often sold online under the guise of a “research chemical not for human use,” a label that is frequently subverted by the same websites providing anecdotal dosing information.59 For athletes subject to anti-doping rules, its use is an explicit violation that can result in sanctions. For medical practitioners, prescribing or administering an unapproved substance like BPC-157 outside of a formal, ethics-board-approved clinical trial raises significant ethical questions and potential legal liability.57

 

5.4 Future Research Imperatives

To resolve the profound uncertainties surrounding BPC-157, a clear and rigorous path of scientific inquiry is required. The absolute priority is the execution of well-designed, large-scale, multicenter, randomized, double-blind, placebo-controlled clinical trials in humans. These trials must be designed to assess both the efficacy and, critically, the short-term and long-term safety of BPC-157 for specific, well-defined clinical indications, such as Achilles tendinopathy or a specific subtype of IBD.

In parallel, further basic science research is needed to fully elucidate its molecular interactions. Identifying a specific, high-affinity receptor for BPC-157, if one exists, would be a major breakthrough. Additionally, more sophisticated animal studies are required to directly investigate its long-term effects on carcinogenesis, for example, by administering it to cancer-prone animal models. Only through such a rigorous, multi-pronged research effort can the true therapeutic potential and risks of BPC-157 be definitively established.

 

6.0 Conclusion

Gastric Pentadecapeptide BPC-157 stands as a compound of immense scientific interest and considerable paradox. The extensive and consistent body of preclinical evidence paints a compelling picture of a pleiotropic, pro-regenerative agent with the potential to fundamentally enhance the body’s healing processes across a vast array of tissues. Its intricate molecular mechanisms—involving the modulation of angiogenesis, sensitization to growth factors, and homeostatic control of inflammation and the nitric oxide system—position it as a uniquely promising therapeutic candidate from a biomedical engineering perspective.

However, this extraordinary preclinical promise is almost entirely untranslated and unverified in the human clinical setting. The potential is overshadowed by a critical void of high-quality human trial data, leaving questions of efficacy and, more importantly, safety, unanswered. The theoretical risk of promoting cancer through its potent pro-angiogenic effects remains a significant and unresolved concern. This scientific uncertainty is mirrored by its regulatory status; it is not approved for human use by the FDA and is explicitly banned for athletes by WADA.

Therefore, BPC-157 currently occupies a precarious position: a subject of fascination for researchers and a substance of high-risk, unproven benefit for the public. Until its safety and efficacy are validated through the rigorous process of controlled clinical trials, its use outside of a formal research context is fraught with unacceptable uncertainty and potential danger. The journey of BPC-157 from a compelling preclinical candidate to a validated clinical therapy, if it is to happen at all, has yet to be navigated.

Works cited

  1. en.wikipedia.org, https://en.wikipedia.org/wiki/BPC-157#:~:text=Gastric%20Pentadecapeptide%20BPC%2D157%20(also,%2DGly%2DLeu%2DVal.
  2. BPC-157: The Healing Peptide – Eternal Youth Aesthetics and Wellness, https://eternalyouthaesthetic.com/wp-content/uploads/2024/12/BPC-157.pdf
  3. BPC-157 – Wikipedia, https://en.wikipedia.org/wiki/BPC-157
  4. Pentadecapeptide BPC 157 Enhances the Growth Hormone …, https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
  5. The promoting effect of pentadecapeptide BPC 157 on tendon …, https://www.researchgate.net/publication/47621674_The_promoting_effect_of_pentadecapeptide_BPC_157_on_tendon_healing_involves_tendon_outgrowth_cell_survival_and_cell_migration
  6. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future – Gut and Liver, https://www.gutnliver.org/journal/view.html?doi=10.5009%2Fgnl18490
  7. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract | Request PDF – ResearchGate, https://www.researchgate.net/publication/51104319_Stable_Gastric_Pentadecapeptide_BPC_157_Novel_Therapy_in_Gastrointestinal_Tract
  8. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review – MDPI, https://www.mdpi.com/1424-8247/18/2/185
  9. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing – Frontiers, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.627533/full
  10. What is BPC-157 (Body Protection Compound) and how can it help?, https://axonintegrativehealth.com/blogs/what-is-bpc-157-body-protection-compound-and-how-can-it-help/
  11. Research Breakdown on BPC-157 – Examine.com, https://examine.com/supplements/bpc-157/research/
  12. BPC 157: Science-Backed Uses, Benefits, Dosage, and Safety – Rupa Health, https://www.rupahealth.com/post/bpc-157-science-backed-uses-benefits-dosage-and-safety
  13. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy – PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/
  14. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing | Request PDF – ResearchGate, https://www.researchgate.net/publication/394451420_Regeneration_or_Risk_A_Narrative_Review_of_BPC-157_for_Musculoskeletal_Healing
  15. BPC 157 promoted in vivo and in vitro angiogenesis. a Representative… – ResearchGate, https://www.researchgate.net/figure/BPC-157-promoted-in-vivo-and-in-vitro-angiogenesis-a-Representative-photos-of-CAMs_fig1_310460258
  16. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts – ResearchGate, https://www.researchgate.net/publication/268790268_Pentadecapeptide_BPC_157_Enhances_the_Growth_Hormone_Receptor_Expression_in_Tendon_Fibroblasts
  17. Regeneration or Risk? A Narrative Review of BPC-157 for …, https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
  18. MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING – Journal of Physiology and Pharmacology, https://jpp.krakow.pl/journal/archive/12_09_s7/pdf/191_12_09_s7_article.pdf
  19. Modulatory effects of BPC 157 on vasomotor tone and the activation …, https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/
  20. (PDF) The Role of BPC-157 in Modulating Inflammation: A …, https://www.researchgate.net/publication/394424135_The_Role_of_BPC-157_in_Modulating_Inflammation_A_Comprehensive_Review
  21. Modulatory effect of gastric pentadecapeptide BPC 157 on …, https://pubmed.ncbi.nlm.nih.gov/20388964/
  22. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.599281/full
  23. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation | Semantic Scholar, https://www.semanticscholar.org/paper/Therapeutic-potential-of-pro-angiogenic-BPC157-is-Hsieh-Liu/81a9b60bdabeb16d5df21ed2b4fa6ae8d97a51ba
  24. Therapeutic potential of pro-angiogenic BPC157 is associated with …, https://www.researchgate.net/publication/310460258_Therapeutic_potential_of_pro-angiogenic_BPC157_is_associated_with_VEGFR2_activation_and_up-regulation
  25. BPC-157 promoted the expression of VEGF-a in wounded skin tissues. – ResearchGate, https://www.researchgate.net/figure/BPC-157-promoted-the-expression-of-VEGF-a-in-wounded-skin-tissues_fig3_277082668
  26. BPC 157 activated VEGFR2 internalization related downstream signaling… – ResearchGate, https://www.researchgate.net/figure/BPC-157-activated-VEGFR2-internalization-related-downstream-signaling-cascades-for_fig5_310460258
  27. (PDF) The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks – ResearchGate, https://www.researchgate.net/publication/339659286_The_influence_of_BPC_157_on_nitric_oxide_agonist_and_antagonist_induced_lesions_in_broiler_chicks
  28. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals 2025, 18, 185 – MDPI, https://www.mdpi.com/1424-8247/18/10/1450
  29. (PDF) Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, https://www.researchgate.net/publication/394166363_Emerging_Use_of_BPC-157_in_Orthopaedic_Sports_Medicine_A_Systematic_Review
  30. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts | MDPI, https://www.mdpi.com/1420-3049/19/11/19066
  31. Growth hormone receptor signaling – Reactome Pathway Database, https://reactome.org/content/detail/R-HSA-982772
  32. JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens, https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1110765/full
  33. BPC-157: Miracle Healing Peptide or Hidden Danger? – Prisk Orthopaedics and Wellness, https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
  34. BPC-157 Research, https://simplepeptide.com/bpc-157
  35. duodenocolic fistula healing by pentadecapeptide bpc 157 in rats. a cytoprotection viewpoint – Journal of Physiology and Pharmacology, https://jpp.krakow.pl/journal/archive/02_24/articles/09_article.html
  36. DUODENOCOLIC FISTULA HEALING BY PENTADECAPEPTIDE BPC 157 IN RATS. A CYTOPROTECTION VIEWPOINT – Journal of Physiology and Pharmacology, https://jpp.krakow.pl/journal/archive/02_24/pdf/10.26402/jpp.2024.1.09.pdf
  37. Nitric oxide induced by BPC 157 contributed to the promoted cell… – ResearchGate, https://www.researchgate.net/figure/Nitric-oxide-induced-by-BPC-157-contributed-to-the-promoted-cell-migration-a-HUVECs_fig4_345388837
  38. (PDF) Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review – ResearchGate, https://www.researchgate.net/publication/388540011_Multifunctionality_and_Possible_Medical_Application_of_the_BPC_157_Peptide-Literature_and_Patent_Review
  39. Healing or Hype? Systematic Review of BPC-157 in Orthopedic Sports Medicine Applications – Mira Smart Conferencing, https://index.mirasmart.com/AAOS2025/PDFfiles/AAOS2025-009087.PDF
  40. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats – MDPI, https://www.mdpi.com/2227-9059/9/11/1547
  41. (PDF) Stable gastric pentadecapeptide BPC 157 heals cysteamine …, https://www.researchgate.net/publication/259200103_Stable_gastric_pentadecapeptide_BPC_157_heals_cysteamine-colitis_and_colon-colon-anastomosis_and_counteracts_cuprizone_brain_injuries_and_motor_disability
  42. (PDF) BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients lowsphincters pressure – ResearchGate, https://www.researchgate.net/publication/51977023_BPC_157_therapy_to_detriment_sphincters_failure-esophagitis-pancreatitis_in_rat_and_acute_pancreatitis_patients_lowsphincters_pressure
  43. Pharmacokinetics, distribution, metabolism, and excretion … – Frontiers, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1026182/full
  44. Pentadecapeptide BPC 157 and the central nervous system – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/
  45. (PDF) Stable gastric pentadecapeptide BPC 157 can improve the …, https://www.researchgate.net/publication/334178882_Stable_gastric_pentadecapeptide_BPC_157_can_improve_the_healing_course_of_spinal_cord_injury_and_lead_to_functional_recovery_in_rats
  46. (PDF) Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy – ResearchGate, https://www.researchgate.net/publication/361219324_Novel_Therapeutic_Effects_in_Rat_Spinal_Cord_Injuries_Recovery_of_the_Definitive_and_Early_Spinal_Cord_Injury_by_the_Administration_of_Pentadecapeptide_BPC_157_Therapy
  47. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury – ResearchGate, https://www.researchgate.net/publication/38080242_Peptide_therapy_with_pentadecapeptide_BPC_157_in_traumatic_nerve_injury
  48. BPC-157 and Muscle/Tissue Healing: A Narrative Review (2019–2024) – ResearchGate, https://www.researchgate.net/publication/390200938_BPC-157_and_MuscleTissue_Healing_A_Narrative_Review_2019-2024
  49. (PDF) Antiinflammatory effect of BPC 157 on experimental periodontitis in rats, https://www.researchgate.net/publication/51443022_Antiinflammatory_effect_of_BPC_157_on_experimental_periodontitis_in_rats
  50. Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System – J-Stage, https://www.jstage.jst.go.jp/article/jphs/108/1/108_FP0072161/_article/-char/en
  51. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights – Baishideng Publishing Group, https://www.wjgnet.com/1007-9327/full/v23/i48/8465.htm
  52. Is BPC 157 (Body Protection Compound 157) effective as a primary treatment for Crohn’s disease? – Dr.Oracle, https://www.droracle.ai/articles/298681/bpc-157-in-crohns-disease
  53. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity – MDPI, https://www.mdpi.com/1424-8247/17/4/461
  54. Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats – Frontiers, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.718147/full
  55. BPC-157 increased wound reepithelialization and collagen content of granulation tissue., https://www.researchgate.net/figure/BPC-157-increased-wound-reepithelialization-and-collagen-content-of-granulation-tissue_fig2_277082668
  56. What Science ACTUALLY Says About BPC 157 Benefits – YouTube, https://www.youtube.com/watch?v=gaQwrB8HW4o
  57. The Dangers of Using BPC-157 as a “Prescribed” Peptide for Musculoskeletal Injuries, https://www.orthoandwellness.com/blog/the-dangers-of-using-bpc-157-as-a-prescribed-peptide-for-musculoskeletal-injuries
  58. Study Details | NCT02637284 | PCO-02 – Safety and Pharmacokinetics Trial | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT02637284
  59. BPC-157: Experimental Peptide Creates Risk for Athletes – U.S. Anti-Doping Agency, https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
  60. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds | Request PDF – ResearchGate, https://www.researchgate.net/publication/340869412_Preclinical_safety_evaluation_of_body_protective_compound-157_a_potential_drug_for_treating_various_wounds
  61. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds – PubMed, https://pubmed.ncbi.nlm.nih.gov/32334036/
  62. Anyone tried BPC157 | Mayo Clinic Connect, https://connect.mayoclinic.org/discussion/anyone-tried-bpc157/
  63. BPC-157 Research, https://alphaomegapeptide.com/bpc-157
  64. 503A Categories Update for September 2024 – FDA, https://www.fda.gov/media/94155/download